Clinical trials
Phase 1 Immune System Diseases trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
35 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 20 |
| Active, not recruiting | 7 |
| Recruiting | 4 |
| Unknown status | 2 |
| Suspended | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| UNC Lineberger Comprehensive Cancer Center | 5 |
| Kadmon, a Sanofi Company | 4 |
| Memgen, LLC | 3 |
| Fred Hutchinson Cancer Center | 2 |
| Stanford University | 2 |
| Acerta Pharma BV | 1 |
| Bioverativ, a Sanofi company | 1 |
| Cabaletta Bio | 1 |
| Celularity Incorporated | 1 |
| City of Hope Medical Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Immune System Diseases | 35 |
| Autoimmune Diseases | 9 |
| Immunoproliferative Disorders | 9 |
| Neoplasms | 7 |
| Lymphoma | 6 |
| Lymphoproliferative Disorders | 6 |
| Hematologic Diseases | 5 |
| Neoplasms by Histologic Type | 5 |
| Communicable Diseases | 4 |
| Leukemia | 4 |
Trials
Showing 1 to 25 of 35. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.